Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
123.3 USD +5.01% Intraday chart for Sarepta Therapeutics, Inc. -5.04% +27.89%
Jun. 03 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000 CI
Jun. 03 Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000
CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology
CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 Health Care
CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P Composite 1500
CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400
CI
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
MT
Sector Update: Health Care
MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Inflation Data
MT
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400
MT
Sarepta Therapeutics Shares Fall After RBC Downgrade
MT
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157
MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating
MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180
MT
Sarepta Therapeutics : P.413-251 Seo et al. In situ biodistribution & localization of SRP-9003 in LGMD2ER4 Mice
PU
Sarepta Therapeutics - Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
AQ
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
BU
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating
MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. News Sarepta Therapeutics, Inc.